Saroglitazar Versus Simvastatin for Metabolic and Alcohol-Associated Liver Disease (MetALD).

Cureus · 2025 · PMC12240681 · PMID 40642726

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP = 0.08so close (0.05 < p ≤ 0.1)

The reduction in CAP score was greater in the saroglitazar group (-40 (-109 to 3) dB/m) compared to the simvastatin group (-33 (-100 to 36) dB/m), although this difference did not reach statistical significance (P = 0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.